Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 0.48 |
| ▸ | PPARG | P37231 | 11/20 | 0.48 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 8/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4065936 | 1.00 | PPARA (0.48) | PPARAPPARGBCHEPPARDPOLB | |
| SCHEMBL3960100 | 0.97 | PPARA (0.49) | PPARAPPARGPPARDPOLBUSP2 | |
| SCHEMBL3961310 | 0.93 | POLB (0.43) | PPARAPPARGBCHEPPARDPOLB | |
| SCHEMBL3967928 | 0.89 | POLB (0.45) | PPARAPPARGBCHEPPARDPOLB | |
| SCHEMBL3962882 | 0.86 | POLB (0.55) | PPARAPPARGPPARDPOLB | |
| SCHEMBL3967710 | 0.84 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL3963119 | 0.84 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL3964391 | 0.84 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL6049558 | 0.84 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL3961311 | 0.84 | POLB (0.45) | BCHEPOLBUSP2HSD17B10ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675820-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | claimed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | claimed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | claimed |
| WO-2004113270-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | claimed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-20070244198-A1 | Carboxylic Derivatives | LI LANNA | 2007-10-18 | — | — | US | disclosed |
| US-20060258866-A1 | Carboxylic derivates | ASTRAZENECA AB, A SWEDEN CORPORATION | 2006-11-16 | — | — | US | disclosed |
| EP-1676833-A1 | Propionic acid derivatives useful in the treatment of lipid disorders | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1675820-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | US | disclosed |
| WO-2004113270-A2 | PROPIONIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF LIPID DISORDERS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244198-A1 | Carboxylic Derivatives | GPR119, CPT1A, PC | PPARA 138/4885PPARG 56/4885BCHE 1133/4885 |
| US-20050148656-A1 | 3-(amino-oxo(alkyl, alkyloxy and alkylthio)phenyl) propanoic and propenoic acid derivatives; peroxisome proliferator-activated receptors agonists; dyslipidemias with or without insulin resisitance and associated metabolic disorders (metabolic syndrome) including obesity, hypertension, type 2 diabetes | GPR119, PPARA, PPARG | PPARA 2/4885PPARG 3/4885BCHE 4358/4885 |
| US-20060258866-A1 | Carboxylic derivates | GPR119, PC, CPT1A | PPARA 145/4885PPARG 91/4885BCHE 911/4885 |
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885BCHE 2688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.